glp 1 with most weight loss Control GLP-1 Costs Nutrition-First Approach GLP-1 Antagonists Increase Plan Drug

8 Future directions The advancement of GLP-1 receptor agonists is progressing towards more refined treatment strategies, with tirzepatide at the forefront of research as a dual GIP/GLP-1 receptor agonist (Nauck and DAlessio 2022)

95% CI, 1.20 to 1.50) [23]

speakers bureau and consulting fees from Amgen, Aegerion, Sanofi, and Regeneron until April 2019 (fees paid to the academic institution)

( PMID: 30115742 ) Trujillo J (2020) Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes

The success of these medicines has spurred development of next-generation GLP-1-based drugs, promising greater weight loss, improved tolerability and additional options for the route and frequency of dosing

Funding This work was supported by Statutory Funds of the Laboratory of Immunoendocrinology, Maj Institute of Pharmacology, Cracow, Poland